Featured by Newsweek & World Class Media Outlets
Dr. Tom Madden

Dr. Tom Madden

Co-Founder & CEO
Acuitas Therapeutics
05 May 2026

Acuitas Therapeutics is a Vancouver-based biotechnology company specialising in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics.  The company partners with pharmaceutical and biotech organisations to enable the development and clinical advancement of mRNA, gene editing and other RNA-based medicines. Its LNP technology has been globally recognised and is a key component in approved therapies and vaccines, including mRNA-based medicines.

In layman’s terms, what do lipid nanoparticles look like, and why are they essential to modern medicine, such as mRNA vaccines?

They are microscopic lipid spheres that wrap the drug inside so that it’s protected, before carrying the drug in the body to cells. This triggers uptake, releasing the drug within the cell where it needs to be to work.

During the pandemic, we described it as ordering a fragile glass vase online. Our technology protects the vase during delivery, brings it to your front door, lets itself into your house, and then opens its own package!

What is driving the current momentum behind LNP technology and nucleic acid therapeutics in modern drug development?

The clinical need remains compelling. While the macro environment has its complexities, from a technical and clinical perspective, the need is as urgent as ever. We are working with partners on mRNA vaccines for diseases like influenza and RSV, and also more challenging ones like malaria and HIV, where mRNA versatility could provide breakthroughs.

Another major area is gene and epigenetic editing, where there is strong interest in correcting genetic errors. About half of our work with partners is in this space. We are also excited about targeted delivery—particularly to T-cells. This includes in vivo CAR-T approaches targeting cancer cells, and work in autoimmune diseases where T-cells are re-coded to attack the B-cells driving disease; one of the most exciting and novel applications for the technology.

What makes LNP delivery uniquely suited to applications like gene editing, epigenetics, and personalised therapies?

Historically, viral vectors have been used to deliver payloads, but they present challenges. One major issue is that patients develop an immune response, so you cannot re-dose them. They are also expensive to produce and difficult to manufacture consistently, which raises regulatory concerns.

In contrast, LNP can be re-dosed without triggering immune responses. This allows dosing to effect, administering multiple doses to achieve clinical outcomes. They are also considered a platform technology by regulators, meaning once safety and efficacy are demonstrated, the same delivery system can be used across multiple genetic diseases. We're seeing an evolution in the regulatory landscape in terms of how regulatory agencies consider new applications, particularly for rare diseases. 

Are there any challenges or concerns with LNP?

We are working with many companies, particularly in gene editing, all using different modalities—base editing, prime editing, RNA writers, epigenetic editors. Each has different payload requirements and potency.

Our focus is ensuring our delivery technology has a sufficiently wide therapeutic index to accommodate all these modalities. We continue to invest heavily in research to broaden that therapeutic index, particularly for gene and epigenetic editing products, and to remain leaders in the space.

Canada has strong life sciences foundations but struggles to scale companies. What gaps need addressing?

The Canadian landscape is fragmented. There are centres of excellence like Vancouver, Montreal, and Toronto, but not at the same concentration of companies as in US hubs like Boston-Cambridge. And with that concentration, you also get access to capital and expertise in those locations.

While Canada has excellent universities and research, scaling becomes difficult. There is a lack of expertise in clinical trials and regulatory processes, and infrastructure for clinical trials is lacking. The regulatory landscape is convoluted—we’ve had partners abandon trials in Canada out of frustration. Our regulatory body isn’t particularly earth-shattering in terms of the initiative it takes—we tend to play a wait-and-see role. As a result, when companies move into clinical trials, they almost invariably set up a subsidiary in the US and source the people they need there. It’s very rare that you see that happening from Canada, and that becomes a real limitation over time.

Are there still benefits to being a Canadian company?

Absolutely.

Vancouver is the global epicentre for LNP research, so we can recruit locally with strong expertise. [We may not be representative of all Canadian biotech companies], but we benefit from this concentration of talent.

Canada’s social systems, education, and infrastructure are also important. There is stability in living and working in Canada, which remains an attractive factor and may become increasingly important for companies.

Acuitas enables partners rather than developing its own drugs. How does that shape your strategy?

We had followed the conventional biotech model before—VC funding, IPOs—and recognised the challenges: constant focus on short-term objectives, share price, and fundraising. We chose not to repeat that model.

Instead, we built a near-term revenue-positive model with long-term revenue from milestones and royalties. We partner exclusively and focus on technology, enabling partners to advance products. This avoids the need for large clinical, regulatory, and manufacturing infrastructure and allows us to dedicate resources to research. We have remained private and self-funded.

Will there be a long-term future for this partnership model as more companies develop in-house capabilities?

Competition increases with success. Some companies develop in-house capabilities, others replicate our model. The key is continuing to advance the technology and stay ahead.

We currently have around 25–30 partner programs in clinical phases, which provides strong validation. This clinical data feeds directly back into our research. What differentiates us is our full “soup to nuts” capability—we support process development, scale-up, and provide clinical and regulatory expertise. This ability to de-risk partner programs is highly attractive.

Following your recent acquisition of RNA Technologies & Therapeutics, should we expect further expansion over the next 12 months? What will drive that?

Working with many biotech companies, we observed inconsistency in mRNA payload quality—some payloads are 10 times more active than others, reflecting differences in design and synthesis. Designing high-quality mRNA is challenging, and scaling to cGMP manufacturing introduces further issues.

We had been working with experts from the University of Pennsylvania and CHOP, and later with RNA technology and therapeutics in Montreal. We were impressed by their quality and consistency, and recognised their expertise as valuable to our partners. This led to us taking a majority position in the company, while allowing them to continue operating independently and connecting them with partners who can benefit from their expertise.